News

CGeneTech Receives Project Support from the "13th Five-Year Plan National Major New Drug Creation Project

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-12-07
  • Views:0

(Summary description)Recently, the National Health and Family Planning Commission (NHFPC) Medical and Health Science and Technology Development Research Center officially issued the "Notification of 2018 Projects for Major New Drug Creation" to enterprises that have received project support. CGeneTech's "Research and development of ESP-8012, a new hypoglycemic dipeptidyl peptidase inhibitor (chemical 1)" was awarded the project support of the National Major New Drug Creation Project during the 13th Five-Year Plan period, and received the first installment of 2018 central financial support. The project has been successfully included in the national level of innovative drug priority support track.

CGeneTech Receives Project Support from the "13th Five-Year Plan National Major New Drug Creation Project

(Summary description)Recently, the National Health and Family Planning Commission (NHFPC) Medical and Health Science and Technology Development Research Center officially issued the "Notification of 2018 Projects for Major New Drug Creation" to enterprises that have received project support. CGeneTech's "Research and development of ESP-8012, a new hypoglycemic dipeptidyl peptidase inhibitor (chemical 1)" was awarded the project support of the National Major New Drug Creation Project during the 13th Five-Year Plan period, and received the first installment of 2018 central financial support. The project has been successfully included in the national level of innovative drug priority support track.

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-12-07
  • Views:0

Recently, the National Health and Family Planning Commission (NHFPC) Medical and Health Science and Technology Development Research Center officially issued the "Notification of 2018 Projects for Major New Drug Creation" to enterprises that have received project support. CGeneTech's "Research and development of ESP-8012, a new hypoglycemic dipeptidyl peptidase inhibitor (chemical 1)" was awarded the project support of the National Major New Drug Creation Project during the 13th Five-Year Plan period, and received the first installment of 2018 central financial support. The project has been successfully included in the national level of innovative drug priority support track.

During the "13th Five-Year Plan" period, the "Major New Drug Creation" Science and Technology Major Project mainly focuses on malignant tumors, cardiovascular and cerebrovascular diseases, drug-resistant pathogenic infections, viral infections and other major diseases, with a focus on supporting original drugs with independent intellectual property rights, high clinical value, good market prospects, and in the preclinical and clinical research stages. Based on the long-term development needs, actively translate and apply the latest achievements of basic research related to new drug development at home and abroad, and carry out innovative drug discovery research based on new targets and new mechanisms of action. Drug discovery research.


China is a major diabetic country with more than 100 million diabetic patients, ranking first in the world. CGeneTech (Suzhou, China) Co., Ltd. was approved by the State Food and Drug Administration of China in May 2017 for the clinical trial of Shengliptin phosphate, a Class 1 innovative drug for the treatment of type 2 diabetes. At present, CGeneTech has reached an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the phase I clinical trial of Shenggliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycemia and weight gain, and has cardiovascular protection; at the same time, Chinese patients with type 2 diabetes are more severely damaged by pancreatic β-cells than those in Europe and the United States, and one of the characteristics of DPP-4 inhibitors is that they can improve β-cell damage, thus Chinese patients can benefit more. This has led to the increasing acceptance of DPP-4 inhibitors by physicians in China.


With a team of elites in the biopharmaceutical industry, CGeneTech has developed a new class 1 glucose-lowering drug, Centagliptin, to bring new hope to the 114 million diabetes patients in China. When compared with the best glucose-lowering drugs in the world, Shengliptin outperforms its competitors in terms of efficacy, safety and cost of administration, and is expected to be the first independently developed new diabetes drug approved for marketing in China.

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO